A team of researchers from Brigham & Women’s Hospital, Mass. Institute of Technology and Mass. General Hospital demonstrated that localizing the delivery of NAMPT inhibitors can extend survival in a mouse model of glioma, according to a paper published this week in the Proceedings of the National Academy of Sciences.
The scientists created a test to check for a mutation linked to glioma and implanted microparticles that slowly elute drug over the course of several days or even weeks to treat the brain cancer.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.